This summary draws on two SEC EDGAR Form 8-K filings, one published on November 18, 2024, and a second published on November 25, 2024, reflecting the staged disclosure typical of a Chapter 11 process. The transaction's current status is pending regulatory review.
The advisory roster reflects the multi-constituency nature of a bankruptcy sale process. Piper Sandler & Co. is serving as investment banker to CareMax, the debtor, in a lead role, a mandate referenced twice in the source material. Alvarez & Marsal North America, LLC is also serving as financial advisor to CareMax, likewise in a lead capacity, again referenced in two separate source sentences. On the creditor side, Guggenheim Securities, LLC is serving as financial advisor and investment banker to the current secured lenders, in a lead role. On the buyer side, Raymond James & Associates, Inc. is serving as investment banker to ClareMedica and its affiliates, the acquiring entity associated with Revere Medical, and Ernst & Young LLP is serving as financial advisor to ClareMedica, both in lead roles.
Legal counsel also reflects this multi-party structure. Sidley Austin LLP is serving as legal counsel to CareMax, referenced twice in the source material. Ropes & Gray LLP is serving as legal counsel to the current secured lenders, alongside Guggenheim Securities' financial advisory role for that same creditor group. McGuireWoods LLP is serving as legal counsel to ClareMedica, alongside Ernst & Young LLP's financial advisory role for that buyer entity.
The facts block identifies this as a Chapter 11 asset sale conducted under a prearranged plan, meaning the sale terms were negotiated with key creditor constituencies before the bankruptcy filing, specifically involving the sale of CareMax's MSO business to Revere Medical and ClareMedica, but it does not disclose the specific purchase price, the treatment of other creditor classes, or the timeline for plan confirmation.
Several material facts are not disclosed. The transaction's dollar value is explicitly stated as not disclosed in the source document. No sector classification is given beyond CareMax's own healthcare designation. No expected plan confirmation or closing date is given, and no detail on the treatment of unsecured creditors or equity holders under the prearranged plan is provided.